The multiple sclerosis gut microbiome and disease activity: A systematic review
Multiple Sclerosis and Related Disorders · 2024-12 · 92 · 106151
DOI: 10.1016/j.msard.2024.106151 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Multiple Sclerosis and Related Disorders, 2024-12. Verfasst von Sophia Jette und 3 weiteren Autor:innen. Beteiligte Einrichtung: Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Multiple Sclerosis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The gut microbiome is a potential therapeutic target for multiple sclerosis (MS), yet its association with disease activity remains unclear. We systematically reviewed the literature to investigate the relationship between the gut microbiome and MS disease activity, course, and disability progression. METHODS: We searched MEDLINE, EMBASE, Web of Science and Google Scholar (01/2011-02/2024) to identify relevant observational or interventional studies published in English. Case reports were ineligible. Outcomes included disease activity (e.g. relapses, MRI), course (e.g. relapsing-remitting/secondary-progressive [RR/SPMS]) and disability progression (e.g. using the Expanded Disability Status Scale [EDSS]). Study quality was evaluated using the Newcastle-Ottawa Scale. RESULTS: Four longitudinal and nineteen cross-sectional studies were included, totaling 1760 persons with MS. Most were female (1237/1760, 70 %) and had RRMS (1378/1760, 78 %). The majority of studies (67 %;10/15) examining gut diversity (alpha or beta) did not find an association with disease activity, course or progression. However, several gut taxa exhibited significant associations with study outcomes, including eight that varied in consistent directions: a higher abundance of Actinobacteria, Bacteroidota and Roseburia inulinivorans were associated with better MS outcomes (e.g. lower EDSS scores), while higher abundances of Streptococcus, Clostridium nexile, Clostridium scindens and Collinsella aerofaciens were associated with worse outcomes (e.g. higher MRI lesion volumes). CONCLUSIONS: Gut diversity was not associated with MS-related outcomes in most studies whereas several gut taxa were, including higher abundances of short chain-fatty acid producers (e.g. Bacteroidota) showing associations with lower EDSS scores. Most studies were cross-sectional, limiting interpretation of findings; longitudinal studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada.
- Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
- Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
- Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada. Electronic address: helen.tremlett@ubc.ca.
Zitieren
APA
Jette, S., de Schaetzen, C., Tsai, C. C., & Tremlett, H. (2024). The multiple sclerosis gut microbiome and disease activity: A systematic review. Multiple Sclerosis and Related Disorders, 92, 106151. https://doi.org/10.1016/j.msard.2024.106151
Vancouver
Jette S, de Schaetzen C, Tsai CC, Tremlett H. The multiple sclerosis gut microbiome and disease activity: A systematic review. Multiple Sclerosis and Related Disorders. 2024;92:106151. doi:10.1016/j.msard.2024.106151
BibTeX
@article{Jette2024,
author = {Jette, Sophia and de Schaetzen, Constance and Tsai, Chia-Chen and Tremlett, Helen},
title = {The multiple sclerosis gut microbiome and disease activity: A systematic review},
journal = {Multiple Sclerosis and Related Disorders},
year = {2024},
volume = {92},
pages = {106151},
doi = {10.1016/j.msard.2024.106151}
}
EUVIMED